Generated by AI
Spruce Biosciences, Inc. is a biopharmaceutical company focused on developing and commercializing novel therapies for rare neurological and endocrine disorders with significant unmet medical need. Its current portfolio centers on enzyme replacement and small-molecule programs designed to address serious diseases where treatment options are limited or inadequate. The company’s work includes therapies for conditions such as Sanfilippo Syndrome Type B and congenital adrenal hyperplasia, reflecting its emphasis on targeted medicines for underserved patient populations. Spruce Biosciences, Inc. operates in the biotechnology sector and participates in the broader rare-disease market, where specialized clinical development and regulatory expertise are essential to bringing therapies to patients. Headquartered in South San Francisco, California, the company is positioned as a development-stage biopharmaceutical business concentrated on advancing precision treatments for complex disorders.
Website611 Gateway Boulevard
South San Francisco, CA, 94080
United States
The latest articles about SPRB.
Summary of Apr 22's posts. Generated by AI.
Summary of Nov 5's posts. Generated by AI.
Summary of Mar 25's posts. Generated by AI.
Investors talking about SPRB also mention these. Each card shows that asset’s own numbers for the past 24 hours.
Valuation and earnings.